Five cases of patients with systemic connective tissue diseases (CTD) who developed connective tissue disease-associated interstitial lung disease (CTD-ILD) with progressive pulmonary fibrosis (PPF) are reported here. Unspecified ILD was diagnosed using high-resolution computed tomography (HRCT). Histologically, all cases were usual interstitial pneumonia (UIP) with findings of advanced (3/5) to diffuse (2/5) fibrosis, with a partially (4/5) to completely (1/5) formed image of a honeycomb lung. The fibrosis itself spread subpleurally and periseptally to more central parts (2/5) of the lung, around the alveolar ducts (2/5), or even without predisposition (1/5). Simultaneously, there was architectural reconstruction based on the mutual fusion of fibrosis without compression of the surrounding lung parenchyma (1/5), or with its compression (4/5). The whole process was accompanied by multifocal (1/5), dispersed (2/5), or organized inflammation in aggregates and lymphoid follicles (2/5). As a result of continuous fibroproduction and maturation of the connective tissue, the alveolar septa thickened, delimiting groups of alveoli that merged into air bullae. Few indistinctly visible (2/5), few clearly visible (1/5), multiple indistinctly visible (1/5), and multiple clearly visible (1/5) fibroblastic foci were present. Among the concomitant changes, areas of emphysema, bronchioloectasia, and bronchiectasis, as well as bronchial and vessel wall hypertrophy, and mucostasis in the alveoli and edema were observed. The differences in the histological appearance of usual interstitial pneumonia associated with systemic connective tissue diseases (CTD-UIP) versus the pattern associated with idiopathic pulmonary fibrosis (IPF-UIP) are discussed here. The main differences lie in spreading lung fibrosis, architectural lung remodeling, fibroblastic foci, and inflammatory infiltrates.

Cancer Research Institute Biomedical Research Centre of the Slovak Academy of Sciences Bratislava Slovak Republic

Centre of Chest Surgery National Institute for Tuberculosis Lung Diseases and Thoracic Surgery in Vyšné Hágy Slovak Republic

Department of Clinical Neurosciences Ostrava University Hospital Ostrava Poruba Czech Republic

Department of Histology and Embryology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Pathology National Institute for Tuberculosis Lung Diseases and Thoracic Surgery in Vyšné Hágy Slovak Republic

Department of Pneumology National Institute for Tuberculosis Lung Diseases and Thoracic Surgery in Vyšné Hágy Slovak Republic

Department of Zoology Faculty of Natural Sciences Comenius University Bratislava Slovak Republic

Zobrazit více v PubMed

Alhamad E.H. (2015). Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia. J. Thorac. Dis. 7, 386-393. PubMed PMC

Ali M.F., Egan A.M., Shaughnessy G.F., Anderson D.K., Kottom T.J., Dasari H., van Keulen V.P., Aubry M.C.-H., Yi E.S., Limper A.H., Peikert T. and Carmona E.M. (2021). Antifibrotics Modify B-Cell- induced fibroblast migration and activation in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 64, 722-733. PubMed PMC

Antin-Ozerkis D., Rubinowitz A., Evans J., Homer R.J. and Matthay R.A. (2012). Interstitial lung disease in the connective tissue diseases. Clin. Chest. Med. 33, 123-149. PubMed

Bahner T., Romagnoli M., Girelli F., Clausen M. and Rabe K.F. (2016). The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD)--A practical approach for the pulmonologist. Respir. Med. 113, 80-92. PubMed

Castillo D., Walsh S., Hansell D.M., Vasakova M., Cottin V., Altinisik G., Palmucci S., Sterclova M., Harari S., Richeldi L., Vancheri C. and Wells A.U. (2018). Validation of multidisciplinary diagnosis in IPF. Lancet Respir. Med. 6, 88-89. PubMed

Cipriani N.A., Strek M., Noth I., Gordon I.O., Charbeneau J., Krishnan J.A., Krausz T. and Husain A.N. (2012). Pathologic quantification of connective tissue disease-associated versus idiopathic usual interstitial pneumonia. Arch. Pathol. Lab. Med. 136, 1253-1258. PubMed

Cottin V. (2013). Significance of connective tissue diseases featured in pulmonary fibrosis. Eur. Respir. Rev. 22, 273-280. PubMed PMC

Chiang G.C. and Parimon T. (2023). Understanding interstitial lung diseases associated with connective tissue disease (CTD-ILD): genetics, cellular pathophysiology, and biologic drivers. Int. J. Mol. Sci. 24, 2405. PubMed PMC

de Lauretis A., Veeraraghavan S. and Renzoni E. (2011). Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron. Respir. Dis. 8, 53-82. PubMed

Hamblin M., Prosch H. and Vasakova M. (2022). Diagnosis, course and management of hypersensitivity pneumonitis. Eur. Respir. Rev. 31, 210169. PubMed PMC

Kishaba T. (2022). Current perspective of progressive-fibrosing interstitial lung disease. Respir. Investig. 60, 503-509. PubMed

Lee J., Kim K. and Jo Y.S. (2023). Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease- related interstitial lung disease. Respir. Med. 212, 107242. PubMed

Luppi F., Manfredi A., Faverio P., Brun Andersen M., Bono F., Pagni F., Salvarani C., Bendstrup R. and Sebastiani M. (2023). The usual interstitial pneumonia pattern in autoimmune rheumatic diseases. BMC Pulm. Med. 23, 501. PubMed PMC

Makovická M., Vrbenská A., Makovický P., Durcová B., Škarda J., Kamarád V., Miklošová M., Michalčová P., Kráľová K. and Muri J. (2024). Histopathological findings in lung biopsies with usual interstitial pneumonia: Definition of a new classification score for histological fibrotic stages. Gen. Physiol. Biophys. 43, 49-56. PubMed

Matěj R. (2023). Current possibilities of histopathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis. How to do it? Cesk. Patol. 59, 10-17. PubMed

Mathai S. and Danoff S.K. (2016). Management of interstitial lung disease associated with connective tissue disease. Br. Med J. 352, h6819. PubMed PMC

Muri J., Chylikova J., Skarda J., Miklosova M. and Kamarad V. (2022). The role of tumor-associated macrophages in solid malignancies - an overview of current knowledge. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 166, 136-139. PubMed

Prele C.M., Miles T., Pearce D.R., ODonoghue R.J., Garinge C., Barrett L., Birnie K., Lucas A.D., Baltic S., Ernst M., Rinaldi C., Laurent G.J., Knight D.A., Fear M., Hoyne G., McAnulty R.J. and Mutseers S.E. (2022). Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis. Eur. Respir. J. 60, 2101469. PubMed PMC

Pugashetti J.V., Adegunsoye A., Wu Z., Lee C.T., Srikrishnan A., Ghodrati S., Vo V., Renzoni E.A., Wella A.U., Kim Garcia K., Chua F., Newton Ch.A., Molyneaux P.L. and Oldham J.M. (2023). Validation of proposed criteria for progressive pulmonary fibrosis. Am. J. Respir. Crit. Care. Med. 207, 69-76. PubMed PMC

Strand M.J., Sprunger D., Cosgrove G., Fernandez-Perez E.R., Frankel S.K., Huie T.J., Olson A.L., Solomon J., Brown K.K. and Swigris J.J. (2014). Pulmonary functions and survival in idiopathic vs secondary usual interstitial pneumonia. Chest 146, 775-785. PubMed PMC

Strange C. and Highland K.B. (2004). Interstitial lung disease in the patient who has connective tissue disease. Clin. Chest Med. 25, 549-559. PubMed

Teoh A.K.Y., Holland A.E., Morisset J., Flaherty K.R., Wells A.U., Walsh S.L.F., Glaspole I., Wuyts W.A. and Corte T.J. (2022). Essential features of an interstitial lung disease multidisciplinary meeting: An international delphi survey. Ann. Am. Thorac. Soc. 19, 66-73. PubMed

Zhao Y.Y., Lian H.J., Li S., Fang C.L., Huang H. and Xu Z.J. (2018). The role of B-cell activating factor in the differential diagnosis of usual interstitial pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 41, 544-550 (in Chinese). PubMed